iShares International Treasury Bond ETF vs Twist Bioscience Corp — how do they compare? iShares International Treasury Bond ETF trades at $41.2, while Twist Bioscience Corp trades at $124.86 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | TWST | |
|---|---|---|
52-Week High | $43.09 | $124.88 |
52-Week Low | $40.35 | $24.16 |
Market Cap | — | $7.72B |
Sector | — | Health |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
IGOV, an iShares International Treasury Bond ETF, trades at $41.21, showing minimal daily movement with a 0.05% gain. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights significant downside risk due to its high duration exposure amid global inflationary pressures and geopolitical tensions, which could lead to capital losses as benchmark rates rise.
The outlook for IGOV is clouded by macroeconomic headwinds; rising global interest rates pose a substantial risk to its bond holdings. Investment opportunity exists for those seeking international treasury exposure, but caution is warranted due to sensitivity to rate changes and ongoing energy-related market volatility.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Trailing returns across standard periods
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →